Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Primary relevance to vitamin D Vitamin D is a stated subject of this paper.

Vitamin D is a stated subject of this paper; the supporting source evidence is shown below.

Why this paper is included

Supporting source evidence:

We found no indication that higher‐than‐normal vitamin D3 supplementation between ages 0 and 2 years decreases ASD‐related trait scores at ages 6 to 8 years.

Source: Abstract. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Multiple reported designs.

Multiple reported designs

More than one design is explicitly reported; examine the supporting methods.

Meta-analysis unclear · Double-blind reported · Human research reported

Reported blinded roles: investigators.

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

Vitamin D supplementation in the first 2 years and autism spectrum traits at 6 to 8 years: a randomized clinical trial

Source: Article title.

This secondary analysis of the double‐blind randomized clinical trial vitamin D intervention in infants (VIDI) comprised 366 Finnish children aged 6 to 8 years, 177 of whom were randomized to receive 400‐IU and 189 to receive 1,200‐IU daily oral vitamin D3 supplementation between ages 2 weeks and 2 years.

Source: Abstract.

This secondary analysis of the double‐blind randomized clinical trial vitamin D intervention in infants (VIDI) comprised 366 Finnish children aged 6 to 8 years, 177 of whom were randomized to receive 400‐IU and 189 to receive 1,200‐IU daily oral vitamin D3 supplementation between ages 2 weeks and 2 years.

Source: Abstract.

Investigators and participating families were blinded to group assignment.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Vitamin D supplementation in the first 2 years and autism spectrum traits at 6 to 8 years: a randomized clinical trial

Multiple reported designs · Journal of Child Psychology and Psychiatry, and Allied Disciplines · 2026

Original publication title

Vitamin D supplementation in the first 2 years and autism spectrum traits at 6 to 8 years: a randomized clinical trial

Samuel Sandboge; Vilja Seppälä; Sakari Lintula; Elisa Holmlund‐Suila; Helena Hauta‐alus; Eero Kajantie; Outi Mäkitie; Sture Andersson; Katri Räikkönen; Kati Heinonen

© 2026 The Author(s). Journal of Child Psychology and Psychiatry published by John Wiley & Sons Ltd on behalf of Association for Child and Adolescent Mental Health.

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

We found no indication that higher‐than‐normal vitamin D3 supplementation between ages 0 and 2 years decreases ASD‐related trait scores at ages 6 to 8 years. Sex‐stratified analysis suggested an inverse association, among boys, between early life 25(OH)D concentrations and ASD‐related traits, warranting further studies on potential causal direction and sex specificity of associations.

An extract from the source publication. Read it in context.

At a glance

Abstract: What background does the paper provide?

Early life vitamin D levels may be associated with autism spectrum disorder (ASD) and related traits, but causality is unknown. We examine whether higher‐than‐standard vitamin D3 supplementation during the first 2 years, as well as higher pregnancy and childhood 25‐hydroxyvitamin D (25(OH)D) levels and their trajectories, are associated with lower ASD trait scores at ages 6 to 8 years in a non‐clinical cohort.

Source: Background

Abstract: What methods does the paper describe?

This secondary analysis of the double‐blind randomized clinical trial vitamin D intervention in infants (VIDI) comprised 366 Finnish children aged 6 to 8 years, 177 of whom were randomized to receive 400‐IU and 189 to receive 1,200‐IU daily oral vitamin D3 supplementation between ages 2 weeks and 2 years. ASD‐related traits were assessed at mean age 7.2 years (SD 0.4) using the parent‐reported Autism Spectrum Screening Questionnaire (ASSQ). Predictor variables were supplementation group, 25(OH)D concentrations measured during pregnancy and at ages 1 and 2 years, as well as 25(OH)D trajectories (high vs. low) derived from these time points.

Source: Methods

Abstract: Results

None of the predictor variables of interest were associated with the outcome in the full sample. After sex stratification, among boys, 25(OH)D concentrations at 1 and 2 years were inversely associated with ASSQ scores (mean difference −0.2 of normalized SD score (95% CI −0.3 to −0.1, p = .003) and −0.2 (95% CI −0.3 to −0.05, p = .01) per 10 ng/mL 25(OH)D) after adjustment for age, breastfeeding, parental education, maternal depressive symptoms, and season of 25(OH)D assessment as was belonging to the higher 25(OH)D trajectory, −0.45 SD (95% CI −0.79 to −0.10, p = .01).

Source: Results

Abstract: Conclusions

We found no indication that higher‐than‐normal vitamin D3 supplementation between ages 0 and 2 years decreases ASD‐related trait scores at ages 6 to 8 years. Sex‐stratified analysis suggested an inverse association, among boys, between early life 25(OH)D concentrations and ASD‐related traits, warranting further studies on potential causal direction and sex specificity of associations.

Source: Conclusions
Authors’ abstract

Background

Early life vitamin D levels may be associated with autism spectrum disorder (ASD) and related traits, but causality is unknown. We examine whether higher‐than‐standard vitamin D3 supplementation during the first 2 years, as well as higher pregnancy and childhood 25‐hydroxyvitamin D (25(OH)D) levels and their trajectories, are associated with lower ASD trait scores at ages 6 to 8 years in a non‐clinical cohort.

Methods

This secondary analysis of the double‐blind randomized clinical trial vitamin D intervention in infants (VIDI) comprised 366 Finnish children aged 6 to 8 years, 177 of whom were randomized to receive 400‐IU and 189 to receive 1,200‐IU daily oral vitamin D3 supplementation between ages 2 weeks and 2 years. ASD‐related traits were assessed at mean age 7.2 years (SD 0.4) using the parent‐reported Autism Spectrum Screening Questionnaire (ASSQ). Predictor variables were supplementation group, 25(OH)D concentrations measured during pregnancy and at ages 1 and 2 years, as well as 25(OH)D trajectories (high vs. low) derived from these time points.

Results

None of the predictor variables of interest were associated with the outcome in the full sample. After sex stratification, among boys, 25(OH)D concentrations at 1 and 2 years were inversely associated with ASSQ scores (mean difference −0.2 of normalized SD score (95% CI −0.3 to −0.1, p = .003) and −0.2 (95% CI −0.3 to −0.05, p = .01) per 10 ng/mL 25(OH)D) after adjustment for age, breastfeeding, parental education, maternal depressive symptoms, and season of 25(OH)D assessment as was belonging to the higher 25(OH)D trajectory, −0.45 SD (95% CI −0.79 to −0.10, p = .01).

Conclusions

We found no indication that higher‐than‐normal vitamin D3 supplementation between ages 0 and 2 years decreases ASD‐related trait scores at ages 6 to 8 years. Sex‐stratified analysis suggested an inverse association, among boys, between early life 25(OH)D concentrations and ASD‐related traits, warranting further studies on potential causal direction and sex specificity of associations.

Publication and source details

Original title: Vitamin D supplementation in the first 2 years and autism spectrum traits at 6 to 8 years: a randomized clinical trial

Samuel Sandboge; Vilja Seppälä; Sakari Lintula; Elisa Holmlund‐Suila; Helena Hauta‐alus; Eero Kajantie; Outi Mäkitie; Sture Andersson; Katri Räikkönen; Kati Heinonen

Journal of Child Psychology and Psychiatry, and Allied Disciplines · 2026

* Correspondence
Samuel Sandboge, Psychology/Welfare, Faculty of Social Sciences, University of Tampere, Kalevantie 4, 33100 Tampere, Finland; Email: samuel.sandboge@tuni.fi
© 2026 The Author(s). Journal of Child Psychology and Psychiatry published by John Wiley & Sons Ltd on behalf of Association for Child and Adolescent Mental Health.https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. Suomen Lääketieteen Säätiö10.13039/100008723 6838 Academy of Finland10.13039/501100002341 323910355565 Sigrid Juséliuksen Säätiö10.13039/501100006306 Signe ja Ane Gyllenbergin Säätiö10.13039/501100004325 Lastentautien Tutkimussäätiö10.13039/501100005744 Yrjö Jahnssonin Säätiö10.13039/100010114 2022757320247839 Novo Nordisk Fonden10.13039/501100009708 Finska Läkaresällskapet10.13039/100010135 Special Governmental Subsidy for Clinical Research Juho Vainion Säätiö10.13039/501100004037

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-10T23:35:31.223158+00:00

DOI: 10.1111/jcpp.70110 · PMC13265620